Abstract: The present invention relates to a sunscreen composition, which comprises 5 to 50% by weight of at least one UV protective agent; 0.05 to 5% by weight of at least one hydrophobically modified clay mineral; 1 to 60% by weight of at least one oil component; and 0.1 to 4% by weight of at least one associative polymer. The present invention also provide a method of achieving an improved sunscreen protection effect with desirable film morphology and excellent wear properties.

Abstract: The present disclosure relates to an air conditioner and a compressor. The compressor includes: a first cylinder assembly, including a first cylinder body and a first sliding vane, a volume control assembly, including a pressure regulator; wherein the pressure regulator is provided with a storage cavity, and the storage cavity is communicated with the variable volume control cavity; wherein the first sliding vane is configured to slide in a reciprocating manner between the first compression cavity and the variable volume control cavity along the first sliding vane groove, to change the volume of the variable volume control cavity; and the refrigerant introduced into the variable volume control cavity flows between the variable volume control cavity and the storage cavity along with a change of the volume of the variable volume control cavity.

Abstract: An electric-vehicle frame includes a mid-section and an end section. The mid-section has first and second frame rails spaced from each other by a first distance along a cross-vehicle axis defining a battery compartment therebetween. The end-section has first and second frame rails spaced from each other by a second distance along the cross-vehicle axis smaller than the first distance. A first connector is fixed to the first frame rail of the mid-section and to the first frame rail of the end-section. A second connector is fixed to the second frame rail of the mid-section and to the second frame rail of the end-section.

Abstract: A system and method remotely allocate bandwidth among content consumers on a computing network based on optimizing an aggregate objective pertaining to a plurality of flows of content. The system and method create a profile for each flow of the plurality of flows from a content provider to a content consumer on the computing network. Information is stored in each profile based on at least a metric associated with the corresponding flow. A target bandwidth for each profile is computed remotely, based on optimizing an aggregate objective pertaining to the plurality of flows of content. The optimizing is also based on the information stored in their respective profiles. The system and method distribute the bandwidth to each flow of the plurality of flows based on the target bandwidth remotely computed for each profile.

Abstract: The present invention relates to a combination product comprising a limonoid compound (or a pharmaceutically acceptable derivative, ester, stereoisomer, salt or prodrug thereof), and a biguanide compound (e.g., metformin, metformin hydrochloride, buformin, and phenformin). The present invention further relates to a use of the combination product for prevention and/or treatment of a disease associated with diabetes, for lipid-lowering and weight-loss, and the like.

Abstract: The present invention relates to a combination product comprising a limonoid compound (or a pharmaceutically acceptable derivative, ester, stereoisomer, salt or prodrug thereof), and a glucose cotransporter-2 inhibitor (SGLT-2) inhibitor (e.g., canagliflozin, dapagliflozin, empagliflozin, ipragliflozin, luseogliflozin and tofogliflozin). The present invention further relates to a use of the combination product for prevention and/or treatment of a disease associated with diabetes and the like.

Abstract: The present invention relates to a combination product comprising a limonoid compound (or a pharmaceutically acceptable derivative, ester, stereoisomer, salt or prodrug thereof), and a sulfonylurea compound (e.g., glibenclamide, gliclazide, glipizide, gliquidone and glimepiride). The present invention further relates to a use of the combination product for prevention and/or treatment of a disease associated with diabetes and the like.

Abstract: The present invention relates to a combination product comprising a limonoid compound (or a pharmaceutically acceptable derivative, ester, stereoisomer, salt or prodrug thereof), and an a-glucosidase inhibitor (e.g., acarbose, acarbose derivative, voglibose, miglitol and the like). The present invention further relates to a use of the combination product for prevention and/or treatment of a disease associated with diabetes and the like.

Abstract: The present invention relates to a combination product comprising a limonoid compound (or a pharmaceutically acceptable derivative, ester, stereoisomer, salt or prodrug thereof), and a thiazolidinedione compound (e.g., rosiglitazone, pioglitazone and the like). The present invention further relates to a use of the combination product for prevention and/or treatment of a disease associated with diabetes and the like.

Abstract: The present invention relates to a combination product comprising a limonoid compound (or a pharmaceutically acceptable derivative, ester, stereoisomer, salt or prodrug thereof), and a DPP-4 inhibitor (e.g., sitagliptin, saxagliptin, vildagliptin, linagliptin, alogliptin, trelagliptin and omarigliptin). The present invention further relates to a use of the combination product for prevention and/or treatment of a disease associated with diabetes and the like.

Abstract: The present invention relates to a combination product comprising a limonoid compound (or a pharmaceutically acceptable derivative, ester, stereoisomer, salt or prodrug thereof), and a biguanide compound (e.g., metformin, metformin hydrochloride, buformin, and phenformin). The present invention further relates to a use of the combination product for prevention and/or treatment of a disease associated with diabetes, for lipid-lowering and weight-loss, and the like.

Abstract: The present invention discloses a use of neohesperidin or a neohesperidin-containing plant extract in the manufacture of a product for improving and/or promoting skin microcirculation, or for eliminating and/or alleviating diseases or conditions associated with poor skin microcirculation. The present invention also discloses a composition comprising an effective amount of neohesperidin or a neohesperidin-containing plant extract, and to a method for improving and/or promoting skin microcirculation, or eliminating and/or alleviating diseases or conditions associated with poor skin microcirculation, by using neohesperidin. The skin microcirculation of the present invention is preferably eye skin microcirculation.

Abstract: The present invention relates to a pharmaceutical composition comprising: (a) at least one neutral endopeptidase inhibitor or a pharmaceutically acceptable salt or ester thereof, (b) at least one compound represented by formula (I) or a pharmaceutically acceptable salt or ester thereof, and a pharmaceutically acceptable carrier. Combined administration showed better medicinal effects than separate administration.

Abstract: The invention discloses an oral solid preparation containing any one, or a mixture of two or more of crystalline form I, II, III, and IV of the compound represented by formula (A). The oral solid preparation of the present invention disintegrates rapidly, increasing dissolution rate thereof, thereby improving bioavailability. In particular, it is possible to solve the problem that an active material (active ingredient), which is high hygroscopic and becomes sticky after moisture absorption, can not be effectively disintegrated by conventional disintegrants. The present invention further relates to a use of the oral solid preparation in preparing an angiotensin II receptor antagonist or a use thereof in preparing medicine for preventing and/or treating hypertension, chronic heart failure and diabetic nephropathy.

Abstract: The invention relates to a skincare cosmetic composition comprising birch sap, birch bark extract, and optional ingredients commonly used in skincare cosmetics, without water typically added as a separate component.

Abstract: Provided are compositions comprising a MSBODY and a cytotoxic immune cell (e.g., Cytokine-induced killer cell) to form Armed Activated CIK cells (ACCs), wherein the MSBODY comprising a first antigen binding moiety that has specificity for a tumor antigen, and a second antigen binding moiety that binds to the cell. Provided are also methods preparing a composition comprising a MSBODY and a cytotoxic immune cell, and methods for treating patients with CIK cells armed with bispecific antibodies.

Abstract: The present invention relates to a pharmaceutical composition comprising: (a) at least one neutral endopeptidase inhibitor or a pharmaceutically acceptable salt or ester thereof, (b) at least one compound represented by formula (I) or a pharmaceutically acceptable salt or ester thereof, and a pharmaceutically acceptable carrier. Combined administration showed better medicinal effects than separate administration.

Abstract: The invention discloses an oral solid preparation containing any one, or a mixture of two or more of crystalline form I, II, III, and IV of the compound represented by formula (A). The oral solid preparation of the present invention disintegrates rapidly, increasing dissolution rate thereof, thereby improving bioavailability. In particular, it is possible to solve the problem that an active material (active ingredient), which is high hygroscopic and becomes sticky after moisture absorption, can not be effectively disintegrated by conventional disintegrants. The present invention further relates to a use of the oral solid preparation in preparing an angiotensin II receptor antagonist or a use thereof in preparing medicine for preventing and/or treating hypertension, chronic heart failure and diabetic nephropathy.

Abstract: The present invention discloses a use of neohesperidin or a neohesperidin-containing plant extract in the manufacture of a product for improving and/or promoting skin microcirculation, or for eliminating and/or alleviating diseases or conditions associated with poor skin microcirculation. The present invention also discloses a composition comprising an effective amount of neohesperidin or a neohesperidin-containing plant extract, and to a method for improving and/or promoting skin microcirculation, or eliminating and/or alleviating diseases or conditions associated with poor skin microcirculation, by using neohesperidin. The skin microcirculation of the present invention is preferably eye skin microcirculation.

Abstract: The invention relates to a skincare cosmetic composition comprising birch sap, birch bark extract, and optional ingredients commonly used in skincare cosmetics, without water typically added as a separate component.